The morbidity and mortality of systemic lupus erythematosus (SLE) is a subject of intense relevance in the literature, yet descriptions of prolonged and sustained remissions or even cure are barely reported.
In recent decades the life expectancy in SLE patients has improved, but the quality of life seems to be poor compared with other chronic diseases and with the general population.
The immunopathogenesis of SLE is complex and not fully understood, so patients have been treated with nonspecific immunosuppressive therapies. But in recent years, because of advances in basic science, targeted therapies have been developed.
Despite the progress made in treating SLE, currently a cure in SLE seems to be a myth. SLE it seems, remains incurable. A specific treatment has not emerged to directly abrogate a disease-specific autoimmune response. Relapsing manifestations and complications of treatment still remain important markers of morbidity.
ShererYGorsteinAFritzlerMJShoenfeldY. Autoantibody explosion in systemic lupus erythematosus: More than 100 different antibodies found in SLE patients. Semin Arthritis Rheum2004; 34: 501–537.
2.
BorchersATKeenCLShoenfeldY. Surviving the butterfly and the wolf: Mortality trends in systemic lupus erythematosus. Autoimmun Rev2004; 3: 423–453.
3.
GladmanDDUrowitzMB. Morbidity in systemic lupus erythematosus. J Rheumatol1987; 14: 223–226.
4.
CerveraRKhamashtaMAFontJ. Morbidity and mortality in systemic lupus erythematosus during a 10-year period: A comparison of early and late manifestations in a cohort of 1,000 patients. Medicine (Baltimore)2003; 82: 299–308.
5.
KatzUZandman-GoddardG. Drug-induced lupus: An update. Autoimmun Rev2010; 10: 46–50.
6.
Campuzano-MayaG. Proof of an association between Helicobacter pylori and idiopathic thrombocytopenic purpura in Latin America. Helicobacter2007; 2: 265–273.
7.
StasiRSarpatwariASegalJB. Effects of eradication of Helicobacter pylori infection in patients with immune thrombocytopenic purpura: A systematic review. Blood2009; 113: 1231–1240.
8.
De LuisDAVarelaCDe La CalleH. Helicobacter pylori infection is markedly increased in patients with autoimmune atrophic thyroiditis. J Clin Gastroenterol1998; 26: 259–263.
9.
FranceschiFSattaMAMentellaMC. Helicobacter pylori infection in patients with Hashimoto’s thyroiditis. Helicobacter2004; 9: 369–369.
10.
AragonaPMagazzùGMacchiaG. Presence of antibodies against Helicobacter pylori and its heat-shock protein 60 in the serum of patients with Sjögren’s syndrome. J Rheumatol1999; 26: 1306–1311.
11.
SorrentinoDFallerGDeVitaS. Helicobacter pylori associated antigastric autoantibodies: Role in Sjögren’s syndrome gastritis. Helicobacter2004; 9: 46–53.
12.
AvciOEllidokuzESimsekIBuyukgebizBGunesAT. Helicobacter pylori and Behcet’s disease. Dermatology1999; 199: 140–143.
13.
AliMWhiteheadM. Clearance of chronic psoriasis after eradication therapy for Helicobacter pylori infection. J Eur Acad Dermatol Venereol2008; 22: 753–754.
14.
Martin HübnerATenbaumSP. Complete remission of palmoplantar psoriasis through Helicobacter pylori eradication: A case report. Clin Exp Dermatol2008; 33: 339–340.
15.
KikuchiTKobayashiTYamashitaTOhashiKSakamakiHAkiyamaH. Eight-year follow-up of patients with immune thrombocytopenic purpura related to H. pylori infection. Platelets2011; 22: 61–64.
16.
MubarakAHouwenRHWoltersVM. Celiac disease: An overview from pathophysiology to treatment. Minerva Pediatr2012; 64: 271–287.
17.
UramotoKMMichetCJJrThumbooJSunkuJO’FallonWMGabrielSE. Trends in the incidence and mortality of systemic lupus erythematosus, 1950–1992. Arthritis Rheum1999; 42: 46–50.
18.
HalbergPAlsbjornBBalslovJT. Systemic lupus erythematosus: follow-up study of 148 patients: I. Classification, clinical and laboratory findings, course and outcome. Clin Rheumatol1987; 6: 13–21.
19.
JollyM. How does quality of life of patients with systemic lupus erythematosus compare with that of other common chronic illnesses?J Rheumatol2005; 32: 1706–1708.
20.
ThumbooJStrandV. Health-related quality of life in patients with systemic lupus erythematosus: An update. Ann Acad Med Singapore2007; 36: 115–122.
LuijtenKMTekstraJBijlsmaJWBijlM. The Systemic Lupus Erythematosus Responder Index (SRI); a new SLE disease activity assessment. Autoimmun Rev2012; 11: 326–329.
23.
GriffithsBMoscaMGordonC. Assessment of patients with systemic lupus erythematosus and the use of lupus disease activity indices. Best Pract Res Clin Rheumatol2005; 19: 685–708.
24.
GladmanDDUrowitzMBKagalAHallettD. Accurately describing changes in disease activity in systemic lupus erythematosus. J Rheumatol2000; 27: 377–379.
TozmanECSUrowitzMBGladmanDD. Prolonged complete remission in previously severe SLE. Ann Rheum Dis1982; 41: 39–40.
27.
DrenkardCVillaARGarcia-PadillaCPérez-VázquezMEAlarcón-SegoviaD. Remission of systemic lupus erythematosus. Medicine (Baltimore)1996; 75: 88–98.
28.
FormigaFMogaIPacMMitjavilaFRiveraAPujolR. High disease activity at baseline does not prevent a remission in patients with systemic lupus erythematosus. Rheumatology (Oxford)1999; 38: 724–727.
29.
HellerCASchurPH. Serological and clinical remission in systemic lupus erythematosus. J Rheumatol1985; 12: 916–918.
30.
SchneiderM. Response and remission criteria for clinical trials in lupus: What can we learn from other diseases?Lupus1999; 8: 627–631.
31.
SteimanAJGladmanDDIbañezDUrowitzMB. Prolonged serologically active clinically quiescent systemic lupus erythematosus: Frequency and outcome. J Rheumatol2010; 37: 1822–1827.
32.
GladmanDDUrowitzMBKeystoneEC. Serologically active clinically quiescent systemic lupus erythematosus: A discordance between clinical and serologic features. Am J Med1979; 66: 210–215.
33.
Walz LeBlancBAGladmanDDUrowitzMB. Serologically active clinically quiescent systemic lupus erythematosus — predictors of clinical flares. J Rheumatol1994; 21: 2239–2241.
34.
YadinOSarovBNagganLSlorHShoenfeldY. Natural autoantibodies in the serum of healthy women — a five-year follow-up. Clin Exp Immunol1989; 75: 402–406.
35.
MittalGBalakrishnaCMangatGJoshiVR. “Sustained remission” in a case of SLE following megadose cyclophosphamide. Lupus1999; 8: 77–80.
36.
RossiECataniaGTruiniMRavettiGLGrassiaLMarmontAM. Patients with systemic lupus erythematosus (SLE) having developed malignant lymphomas. Complete remission of lymphoma following high-dose chemotherapy, but not of SLE. Clin Exp Rheumatol2011; 29: 555–559.
37.
MoroniGGreloniGCPonticelliC. Late recurrence of lupus nephritis after long-term clinical remission. Nephrol Dial Transplant2001; 16: 849–852.
38.
BurtRKTestoriACraigRCohenBSuffitRBarrW. Hematopoietic stem cell transplantation for autoimmune diseases: What have we learned?J Autoimmun2008; 30: 116–120.
39.
MarmontAM. Hematopoietic stem cell transplantation for systemic lupus erythematosus. Clin Dev Immunol2012; 2012: 380391–380391.
40.
IlleiGGCerveraRBurtRK. Current state and future directions of autologous hematopoietic stem cell transplantation in systemic lupus erythematosus. Ann Rheum Dis2011; 70: 2071–2074.
41.
GualtierottiRBiggioggeroMPenattiAEMeroniPL. Updating on the pathogenesis of systemic lupus erythematosus. Autoimmun Rev2010; 10: 3–7.
42.
MuñozLEJankoCSchulzeC. Autoimmunity and chronic inflammation — two clearance-related steps in the etiopathogenesis of SLE. Autoimmun Rev2010; 10: 38–42.
43.
TsokosGC. Systemic lupus erythematosus. N Engl J Med2011; 365: 2110–2121.
44.
MokCC. Update on emerging drug therapies for systemic lupus erythematosus. Expert Opin Emerg Drugs2010; 15: 53–70.
45.
BezalelSAsherIElbirtDSthoegerZM. Novel biological treatments for systemic lupus erythematosus: Current and future modalities. Isr Med Assoc J2012; 14: 508–514.
46.
MurdacaGColomboBMPuppoF. Emerging biological drugs: A new therapeutic approach for systemic lupus erythematosus. An update upon efficacy and adverse events. Autoimmun Rev2011; 11: 56–60.
47.
SmithKGJonesRBBurnsSMJayneDR. Long-term comparison of rituximab treatment for refractory systemic lupus erythematosus and vasculitis: Remission, relapse, and re-treatment. Arthritis Rheum2006; 54: 2970–2982.
48.
Van VollenhovenRF. Rituximab — shadow, illusion or light?Autoimmun Rev2012; 11: 563–567.
49.
HahnBHSinghRRWongWKTsaoBPBulpittKEblingFM. Treatment with a consensus peptide based on amino acid sequences in autoantibodies prevents T cell activation by autoantigens and delays disease onset in murine lupus. Arthritis Rheum2001; 44: 432–441.
50.
MullerSMonneauxFSchallN. Spliceosomal peptide P140 for immunotherapy of systemic lupus erythematosus: Results of an early phase II clinical trial. Arthritis Rheum2008; 58: 3873–3883.
51.
MozesESharabiA. A novel tolerogenic peptide, hCDR1, for the specific treatment of systemic lupus erythematosus. Autoimmun Rev2010; 10: 22–26.
52.
DiamondBBloomOAl AbedYKowalCHuertaPTVolpeBT. Moving towards a cure: Blocking pathogenic antibodies in systemic lupus erythematosus. J Intern Med2011; 269: 36–44.
FargeDLabopinMTyndallA. Autologous hematopoietic stem cell transplantation for autoimmune diseases: An observational study on 12 years’ experience from the European Group for Blood and Marrow Transplantation Working Party on Autoimmune Diseases. Haematologica2010; 95: 284–292.
55.
DaikelerTLabopinMDi GioiaM. Secondary autoimmune diseases occurring after HSCT for an autoimmune disease: A retrospective study of the EBMT Autoimmune Disease Working Party. Blood2011; 118: 1693–1698.
56.
LohYOyamaYStatkuteL. Development of a secondary autoimmune disorder after hematopoietic stem cell transplantation for autoimmune diseases: Role of conditioning regimen used. Blood2007; 109: 2643–2648.
57.
BohgakiTAtsumiTKoikeT. Multiple autoimmune diseases after autologous stem-cell transplantation. N Engl J Med2007; 357: 2734–2736.
58.
McKendryRJHuebschLLeclairB. Progression of rheumatoid arthritis following bone marrow transplantation: A case report with a 13-year follow-up. Arthritis Rheum1996; 39: 1246–1253.
59.
TapprichCFenkRSchneiderPBernhardtAHaasRKobbeG. Early recurrence of rheumatoid arthritis after nonmyeloablative allogeneic blood stem cell transplantation in a patient with multiple myeloma. Bone Marrow Transplant2003; 32: 629–631.
60.
MarmontAMGualandiFVan LintMTBacigalupoA. Refractory Evans’ syndrome treated with allogeneic SCT followed by DLI. Demonstration of a graft-versus autoimmunity effect. Bone Marrow Transplant2003; 31: 399–402.
